BOSTON-Health care providers are not generally part of the discussion about the future of health care in the United States-but they need to speak up in the perilous times ahead, Harvard University economist Marc J. Roberts, PhD, challenged physicians at the 42nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).
WASHINGTON-Gene therapy is unlikely to cure cancer on its own, but may enhance existing treatments when used in combination, said Chuan-Yuan Li, PhD, of Duke University Medical Center. "Combining gene therapy with radiation therapy produces a synergistic effect on tumors and merits further study," he said at the Susan G. Komen Breast Cancer Foundation grants conference "Reaching for the Cure."
WASHINGTON, DC-Rituximab (Rituxan) given three times per week has significant activity in chronic lymphocytic lymphoma (CLL) and in small lymphocytic lymphoma (SLL), but platelets must be monitored closely in patients with preexisting thrombocytopenia. These results from a phase-I/II rituximab study were described by John C. Byrd, MD, of Walter Reed Medical Center in Washington, DC.
BETHESDA-"BL22 is the first agent since purine analogs capable of inducing complete remission in the majority of patients with hairy cell leukemia, and the only agent that can induce complete remission in most patients with chemotherapy-refractory or variant HCL," according to Robert J. Kreitman, MD. "Its sparing of T cells," he continued, "may also allow improved clearing of minimal residual disease."
HOUSTON-High-dose chemotherapy (HDCT) plus rituximab (Rituxan) produces responses comparable to HDCT with total body irradiation and stem cell transplant for aggressive mantle cell lymphoma (MCL), according to Jorge E. Romaguera, MD, of the University of Texas M. D. Anderson Cancer Center in Houston, Texas. In a poster presentation, Dr. Romaguera said that HDCT with rituximab (but without total body irradiation or stem cell transplant) produced a complete response (CR) rate of 86%.
EAST MELBOURNE, Australia-Dose-intensified CEOP (cyclophosphamide, epirubicin, Oncovin [vincristine], prednisolone) produces significantly more toxicity than a standard dose CEOP regimen (s-CEOP), but does not improve outcome in non-Hodgkin’s lymphoma patients, according to a phase-III trial conducted in Australia and New Zealand by the Australian Leukemia and Lymphoma Group (ALLG).
BOSTON-Women who receive postlumpectomy radiotherapy to their left breast are not at greater risk of heart attacks, according to a study presented by Katherine Vallis, MD, at the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO).
Although bone pain from osteoblastic metastases can be ameliorated 50% to 80% of the time by use of intravenously or orally administered radiopharmaceuticals, we cannot accurately predict who will or will not
Corticosteroids play a vitally important role in the treatment of patients with advanced cancer. While the scientific data, as reviewed by Wooldridge et al, are often slim, most physicians who treat patients with cancer quickly become comfortable with prescribing synthetic glucocorticoids for a variety of indications. Wooldridge et al have provided a much needed synthesis of the medical literature on the use of steroids, both as part of chemotherapeutic treatment for a variety of malignancies and in symptom control.
Drs. Wooldridge, Anderson, and Perry have succinctly reviewed the use of corticosteroids in patients with advanced cancer. The common uses of corticosteroids-namely, the treatment of nausea and vomiting, hypersensitivity reactions, and appetite stimulation-are well covered. In addition, the use of corticosteroids for the treatment of spinal cord compression and bone pain are also reviewed. The authors provide a definitive summary of the available published literature.
Although bone pain from osteoblastic metastases can be ameliorated 50% to 80% of the time by use of intravenously or orally administered radiopharmaceuticals, we cannot accurately predict who will or will not
Although bone pain from osteoblastic metastases can be ameliorated 50% to 80% of the time by use of intravenously or orally administered radiopharmaceuticals, we cannot accurately predict who will or will not
Dr. Subir Nag et al are to be congratulated for their excellent, thorough analysis and presentation of the use and role of
The first attempt at using monoclonal antibodies in lymphoma therapy, reported in 1980, was unsuccessful. Since that time, several immunotherapeutic approaches to treating non-Hodgkin’s lymphoma have been developed,
The article by Nag and colleagues of the American Brachytherapy Society is a well-intentioned effort to establish guidelines
The field of stereotactic radiosurgery is rapidly advancing as a result of both improvements in radiosurgical equipment and better physician understanding of the clinical applications of stereotactic radiosurgery. This
The first attempt at using monoclonal antibodies in lymphoma therapy, reported in 1980, was unsuccessful. Since that time, several immunotherapeutic approaches to treating non-Hodgkin’s lymphoma have been developed,
Physicians who diagnose and treat cancer have an enormous responsibility. They not only have to be aware of the medical aspects of cancer screening, diagnosis, and treatment, but also have the difficult task of talking about these issues with their patients.
Despite impressive response rates, none of the current array of monoclonal antibodies has produced cures. The median duration of response following rituximab is about 1 year, and all patients eventually relapse and require additional treatment
Other active unconjugated antibodies are in various stages of their clinical development. CAMPATH-1H has recently been approved for the treatment of refractory chronic lymphocytic leukemia (Keating et al: Blood 94:705a[abstract 3118],
Once the radioimmunoconjugates (RICs) become more widely available, the practicing physician will be faced with important questions regarding their role relative to the unconjugated antibodies, and with a decision as to which is the
Rituximab is also being explored in other lymphoid malignancies. Some of the most interesting data are in patients with CD20-positive Hodgkin’s disease (abstract #3153). The Stanford group (abstract #3592) reported on 13 patients. Of the 9
The availability of a continually increasing menu of effective monoclonal antibodies has revolutionized the management of patients with indolent B-cell malignancies. The dilemma we now face is how to best incorporate these agents into our
The first attempt at using monoclonal antibodies in lymphoma therapy, reported in 1980, was unsuccessful. Since that time, several immunotherapeutic approaches to treating non-Hodgkin’s lymphoma have been developed,
Whole-breast external-beam radiation therapy (EBRT) involves a 6-week course of fractionated treatments. In
The field of stereotactic radiosurgery is rapidly advancing as a result of both improvements in radiosurgical equipment and better physician understanding of the clinical applications of stereotactic radiosurgery. This
The field of stereotactic radiosurgery is rapidly advancing as a result of both improvements in radiosurgical equipment and better physician understanding of the clinical applications of stereotactic radiosurgery. This
Despite the fact that there are only a few controlled trials demonstrating the benefits associated with the use of corticosteroids in specific situations, these agents are administered frequently to patients with advanced cancer. Corticosteroids may be used alone or as adjuvants in combination with other palliative or antineoplastic treatments. For example, corticosteroids may help prevent nausea, vomiting, and hypersensitivity reactions to treatment with chemotherapy or radiation. They are also commonly used as appetite stimulants in patients with advanced cancer. In the adjuvant setting, corticosteroids help to alleviate pain in advanced cancer patients, including specific situations such as back pain related to epidural compression. This article reviews the evidence supporting the use of corticosteroids in a broad range of situations seen in patients with advanced cancer. [ONCOLOGY 15(2):225-236, 2001]
The second edition of the Textbook of Uncommon Cancer is a useful resource for practicing oncologists who encounter unusual presentations of common tumors or esoteric subtypes of more common cancers. The text is laid out according to
ROCHESTER, Minnesota-Ibritumomab tiuxetan (Zevalin) significantly improves quality of life for patients with low-grade, follicular, or transformed non-Hodgkin’s lymphoma (NHL) patients, according to the results of a phase-III study reported by Gregory A. Wiseman, MD. "Low-grade lymphoma is not a curable disease, but patients live for a long time with it," said Dr. Wiseman, lead researcher and assistant professor, Radiology Department, at the Mayo Clinic in Rochester, Minnesota. "We want to know how patients are feeling, especially if they’re going through difficult treatments. What we discovered is that after receiving Zevalin, patients’ quality of life was good."